Public Market Listing
000100KOSPI
Live quotes, historical charts, and market capitalization for Yuhan Corporation are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
7Total Assets
1Approved
1Phase 3 / Filed
5Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
Sarpogrelate(Anplag) | Phase 3 | Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Atherosclerotic Cardiovascular Disease |
| Phase 1/2 | EGFR x 4-1BB (CD137)Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | HER2 exon 20 insertions; EGFR exon 20 insertionsSmall molecule | Non-Small Cell Lung Cancer | |
RosuampinNo recent activity | Preclinical / Unstaged | HMG-CoA reductase / Calcium channelSmall molecule | HypertensionAtherosclerotic Cardiovascular Disease |
RosuvamibeNo recent activity | Preclinical / Unstaged | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
| Preclinical / Unstaged | HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component)Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2028 (2)
March 2028 (2)
Est. primary completion 2028-03-02 · NCT07586202 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Est. primary completion 2029-05-23 · NCT06667076 · CT.gov ↗